Short‐term FSH treatment and sperm maturation: a prospective study in idiopathic infertile men

The standard FSH treatment is based on a 3 months period, after which both quantitative/qualitative improvement of sperm parameters and increased pregnancy rate were reported. In this prospective clinical trial, for the first time, we studied (i) Sperm hyaluronic acid binding capacity after highly purified FSH (hpFSH) treatment; (ii) the effect after short‐term and standard treatment on this functional parameter. As secondary objective, we analyzed three SNPs on FSHβ and FSHR genes to define their potential predictive value for responsiveness. From a total of 210 consecutive patients, 40 oligo‐ and/or astheno‐ and/or teratozoospermic patients fulfilled the inclusion criteria. Treatment consisted in hpFSH 75 IU/L every other day for 3 months. To avoid potential biases derived from the lack of placebo, we analyzed each patient after 4–6 months of ‘wash‐out’ period. After FSH treatment, we observed a statistically significant (p < 0.001) improvement of the percentage of hyaluronic acid bound spermatozoa from basal to T1 (after 1 month) and to T3 (after 3 months). Importantly, these values returned to near‐baseline value after the wash‐out. The same results were detected for total motile sperm count after 3 months with return to baseline after wash‐out. Forty‐two percent of patients responded to the therapy with increasing hyaluronic acid binding capacity above the double of the Intraindividual Variation (IV) while 24% of patients reached above the normal Sperm‐Hyaluronan Binding Assay (HBA) value. Further increase in ‘responders’ was observed at T3. The responsiveness to treatment resulted independent from FSHR/FSHβ polymorphisms. The significant positive effect on sperm maturity after 1 month opens novel therapeutic perspectives. In view of both the high cost and the relative invasiveness of treatment, the short protocol (1 month) could represent a viable FSH treatment option prior Assisted Reproductive Techniques since FSH, by acting on sperm maturation, increases the proportion of functionally competent cells.

[1]  H. Tournaye,et al.  Novel concepts in the aetiology of male reproductive impairment. , 2017, The lancet. Diabetes & endocrinology.

[2]  H. Tournaye,et al.  Concepts in diagnosis and therapy for male reproductive impairment. , 2017, The lancet. Diabetes & endocrinology.

[3]  E. Baldi,et al.  Treatment with human, recombinant FSH improves sperm DNA fragmentation in idiopathic infertile men depending on the FSH receptor polymorphism p.N680S: a pharmacogenetic study. , 2016, Human reproduction.

[4]  S. Kliesch,et al.  FSHB ‐211G>T stratification for follicle‐stimulating hormone treatment of male infertility patients: making the case for a pharmacogenetic approach in genetic functional secondary hypogonadism , 2015, Andrology.

[5]  D. Santi,et al.  FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis , 2015, Endocrine connections.

[6]  Z. Molnár,et al.  Sperm concentration, hyaluronic acid-binding capacity, aneuploidy and persistent histones in testicular cancer. , 2014, Human reproduction.

[7]  M. Punab,et al.  Reproductive Physiology in Young Men Is Cumulatively Affected by FSH-Action Modulating Genetic Variants: FSHR -29G/A and c.2039 A/G, FSHB -211G/T , 2014, PloS one.

[8]  E. Bosmans,et al.  Semen quality and prediction of IUI success in male subfertility: a systematic review. , 2014, Reproductive biomedicine online.

[9]  G. Ruvolo,et al.  Lower sperm DNA fragmentation after r-FSH administration in functional hypogonadotropic hypogonadism , 2013, Journal of Assisted Reproduction and Genetics.

[10]  K. Ivani,et al.  Use of hyaluronan in the selection of sperm for intracytoplasmic sperm injection (ICSI): significant improvement in clinical outcomes—multicenter, double-blinded and randomized controlled trial , 2012, Human reproduction.

[11]  M. Punab,et al.  Study in 1790 Baltic men: FSHR Asn680Ser polymorphism affects total testes volume , 2012, Andrology.

[12]  Z. Molnár,et al.  Correlation study between sperm concentration, hyaluronic acid-binding capacity and sperm aneuploidy in Hungarian patients. , 2012, Reproductive biomedicine online.

[13]  M. Punab,et al.  Combined effects of the variants FSHB -211G>T and FSHR 2039A>G on male reproductive parameters. , 2012, The Journal of clinical endocrinology and metabolism.

[14]  N. Colacurci,et al.  Recombinant human FSH reduces sperm DNA fragmentation in men with idiopathic oligoasthenoteratozoospermia. , 2012, Journal of andrology.

[15]  A. Frigo,et al.  Toward a pharmacogenetic approach to male infertility: polymorphism of follicle-stimulating hormone beta-subunit promoter. , 2011, Fertility and sterility.

[16]  C. Foresta,et al.  The response to FSH treatment in oligozoospermic men depends on FSH receptor gene polymorphisms. , 2011, International journal of andrology.

[17]  N. Jørgensen,et al.  Genetically Determined Dosage of Follicle-Stimulating Hormone (FSH) Affects Male Reproductive Parameters , 2011, The Journal of clinical endocrinology and metabolism.

[18]  F. Zullo,et al.  Effects of highly purified follicle-stimulating hormone on sperm DNA damage in men with male idiopathic subfertility: A pilot study , 2011, Journal of Endocrinological Investigation.

[19]  C. Krausz Male infertility: pathogenesis and clinical diagnosis. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[20]  Artay Yagci,et al.  Spermatozoa bound to solid state hyaluronic acid show chromatin structure with high DNA chain integrity: an acridine orange fluorescence study. , 2010, Journal of andrology.

[21]  Organización Mundial de la Salud WHO laboratory manual for the examination and processing of human semen , 2010 .

[22]  P. Korrovits,et al.  Increased Prevalance of the -211 T allele of follicle stimulating hormone (FSH) beta subunit promoter polymorphism and lower serum FSH in infertile men. , 2010, The Journal of clinical endocrinology and metabolism.

[23]  S. Kaali,et al.  The role of hyaluronic acid binding assay in choosing the fertilization method for patients undergoing IVF for unexplained infertility , 2010, Journal of Assisted Reproduction and Genetics.

[24]  G. Morgante,et al.  Sperm aneuploidies after human recombinant follicle stimulating hormone therapy in infertile males. , 2009, Reproductive biomedicine online.

[25]  T. Kruger,et al.  Selectivity of hyaluronic acid binding for spermatozoa with normal Tygerberg strict morphology. , 2009, Reproductive biomedicine online.

[26]  M. Punab,et al.  FSHB promoter polymorphism within evolutionary conserved element is associated with serum FSH level in men , 2008, Human reproduction.

[27]  S. Meachem,et al.  Gonadotrophins regulate germ cell survival, not proliferation, in normal adult men. , 2007, Human reproduction.

[28]  E. Delpiano,et al.  Fertility testing and ICSI sperm selection by hyaluronic acid binding: clinical and genetic aspects. , 2007, Reproductive biomedicine online.

[29]  C. Farquhar,et al.  Gonadotrophins for idiopathic male factor subfertility. , 2007, The Cochrane database of systematic reviews.

[30]  Alberto Revelli,et al.  Intracytoplasmic sperm injection: a novel selection method for sperm with normal frequency of chromosomal aneuploidies. , 2005, Fertility and sterility.

[31]  C. Foresta,et al.  Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study. , 2005, Fertility and sterility.

[32]  K. C. Worrilow,et al.  The hyaluronan binding assay (HBA™) has a positive and significant relationship with sperm morphology and chromatin integrity , 2004 .

[33]  P. Piomboni,et al.  Effect of follicle-stimulating hormone on sperm quality and pregnancy rate. , 2004, Asian journal of andrology.

[34]  Ciler Celik Ozenci,et al.  Hyaluronic acid binding by human sperm indicates cellular maturity, viability, and unreacted acrosomal status. , 2003, Fertility and sterility.

[35]  D. Ward,et al.  Biochemical markers of sperm function: male fertility and sperm selection for ICSI. , 2003, Reproductive biomedicine online.

[36]  C. Foresta,et al.  Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. , 2002, Fertility and sterility.

[37]  M. Sousa,et al.  Developmental potential of human spermatogenic cells co-cultured with Sertoli cells. , 2002, Human reproduction.

[38]  K. Stone,et al.  Putative Creatine Kinase M-Isoform in Human Sperm Is Identifiedas the 70-Kilodalton Heat Shock Protein HspA21 , 2000, Biology of reproduction.

[39]  H. Krishnamurthy,et al.  Qualitative and Quantitative Decline in Spermatogenesis of the Follicle-Stimulating Hormone Receptor Knockout (FORKO) Mouse1 , 2000, Biology of reproduction.

[40]  M. Plebani,et al.  FSH in the treatment of oligozoospermia , 2000, Molecular and Cellular Endocrinology.

[41]  J. Jarow Follicle-stimulating hormone treatment for men with idiopathic oligoteratoasthenozoospermia before in vitro fertilization: the impact on sperm microstructure and fertilization potential. , 2000, The Journal of urology.

[42]  E. Nieschlag,et al.  Recombinant human follicle stimulating hormone for treatment of male idiopathic infertility: a randomized, double-blind, placebo-controlled, clinical trial. , 1998, Human reproduction.

[43]  J. Kratzsch,et al.  Effects of pure human follicle‐stimulating hormone (pFSH) on sperm quality correlate with the hypophyseal response to gonadotrophin‐releasing hormone (GnRH) * , 2009, Andrologia.

[44]  P. Piomboni,et al.  The effect of follicle stimulating hormone therapy on human sperm structure (Notulae seminologicae 11). , 1997, Human reproduction.

[45]  B. Lunenfeld,et al.  Sperm quality of subfertile males before and after treatment with human follicle‐stimulating hormone , 1994, Fertility and sterility.